113 related articles for article (PubMed ID: 20649824)
21. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.
Antoun S; Birdsell L; Sawyer MB; Venner P; Escudier B; Baracos VE
J Clin Oncol; 2010 Feb; 28(6):1054-60. PubMed ID: 20085939
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer.
Amato RJ; Flaherty AL; Stepankiw M
Clin Genitourin Cancer; 2012 Mar; 10(1):26-31. PubMed ID: 22169794
[TBL] [Abstract][Full Text] [Related]
24. Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review.
Adjei AA; Blumenschein GR; Mandrekar S; Hillman S; Gatzemeier U; Heigener D
Clin Lung Cancer; 2011 Jul; 12(4):212-7. PubMed ID: 21726819
[TBL] [Abstract][Full Text] [Related]
25. Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure.
Ruppin S; Protzel C; Klebingat KJ; Hakenberg OW
Eur Urol; 2009 Apr; 55(4):986-8; quiz 988. PubMed ID: 19004541
[TBL] [Abstract][Full Text] [Related]
26. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation.
Miyake H; Kurahashi T; Yamanaka K; Kondo Y; Muramaki M; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2010; 28(5):515-9. PubMed ID: 19914105
[TBL] [Abstract][Full Text] [Related]
27. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients.
Bellmunt J; Fishman M; Eisen T; Quinn D
Expert Rev Anticancer Ther; 2010 Jun; 10(6):825-35. PubMed ID: 20553208
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.
Ansari J; Fatima A; Chaudhri S; Bhatt RI; Wallace M; James ND
Onkologie; 2009 Feb; 32(1-2):44-6. PubMed ID: 19209019
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
Wood LS; Manchen B
Clin J Oncol Nurs; 2007 Oct; 11(5):649-56. PubMed ID: 17962173
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
Elser C; Siu LL; Winquist E; Agulnik M; Pond GR; Chin SF; Francis P; Cheiken R; Elting J; McNabola A; Wilkie D; Petrenciuc O; Chen EX
J Clin Oncol; 2007 Aug; 25(24):3766-73. PubMed ID: 17704426
[TBL] [Abstract][Full Text] [Related]
31. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.
Hutson TE; Bellmunt J; Porta C; Szczylik C; Staehler M; Nadel A; Anderson S; Bukowski R; Eisen T; Escudier B;
Eur J Cancer; 2010 Sep; 46(13):2432-40. PubMed ID: 20656473
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib for the management of advanced renal cell carcinoma.
Escudier B
Expert Rev Anticancer Ther; 2011 Jun; 11(6):825-36. PubMed ID: 21707277
[TBL] [Abstract][Full Text] [Related]
33. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
Amato RJ; Jac J; Giessinger S; Saxena S; Willis JP
Cancer; 2009 Jun; 115(11):2438-46. PubMed ID: 19306412
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
Furuse J; Ishii H; Nakachi K; Suzuki E; Shimizu S; Nakajima K
Cancer Sci; 2008 Jan; 99(1):159-65. PubMed ID: 17953709
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib in renal cell carcinoma.
Flaherty KT
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):747s-752s. PubMed ID: 17255304
[TBL] [Abstract][Full Text] [Related]
36. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib: new drug. Second-line treatment of kidney cancer: better evaluated than sunitinib.
Prescrire Int; 2007 Aug; 16(90):141-3. PubMed ID: 17724834
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
Weinmann A; Niederle IM; Koch S; Hoppe-Lotichius M; Heise M; Düber C; Schuchmann M; Otto G; Galle PR; Wörns MA
Dig Liver Dis; 2012 May; 44(5):432-7. PubMed ID: 22265328
[TBL] [Abstract][Full Text] [Related]
39. Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.
Kennoki T; Kondo T; Kimata N; Murakami J; Ishimori I; Nakazawa H; Hashimoto Y; Kobayashi H; Iizuka J; Takagi T; Yoshida K; Tanabe K
Jpn J Clin Oncol; 2011 May; 41(5):647-55. PubMed ID: 21367805
[TBL] [Abstract][Full Text] [Related]
40. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.
Bianchi G; Loibl S; Zamagni C; Salvagni S; Raab G; Siena S; Laferriere N; Peña C; Lathia C; Bergamini L; Gianni L
Anticancer Drugs; 2009 Aug; 20(7):616-24. PubMed ID: 19739318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
